Lin28/let-7 crystal structures, purification protocols, and molecular probes suitable for screening assays and therapeutics

US9593141B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-9593141-B2
Application numberUS-201214357020-A
CountryUS
Kind codeB2
Filing dateNov 9, 2012
Priority dateNov 9, 2011
Publication dateMar 14, 2017
Grant dateMar 14, 2017

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

The invention provides compositions and methods for regulating microRNA (miRNA) biogenesis. The invention also relates to compositions and methods for treating or preventing cancer in a subject in need thereof.

First claim

Opening claim text (preview).

What is claimed is: 1. An RNA oligonucleotide comprising: a. a nucleotide sequence of formula 5′-N 1 N 2 N 3 N 4 N 5 N 6 N 7 N 8 N 9 -3′, wherein N 2 , N 4 , N 5 and N 7 are independently a purine; N 1 , N 3 , N 6 , N 8 , and N 9 are independently a pyrimidine; and b. a nucleotide sequence of 5′-GGAG-3′, wherein the sequence 5′-GGAG-3′ is linked to the 3′ of the sequence of formula 5′-N 1 N 2 N 3 N 4 N 5 N 6 N 7 N 8 N 9 -3′, wherein the sequence 5′-GGAG-3′ is single-stranded, wherein there are from 0 to 25 nucleotides between the 3′ end of 5′-N 1 N 2 N 3 N 4 N 5 N 6 N 7 N 8 N 9 -3′ and 5′ end of the sequence 5′-GGAG-3′, and wherein the RNA oligonucleotide is 18-100 nucleotides in length. 2. The oligonucleotide of claim 1 , wherein the oligonucleotide comprises a hairpin structure comprising a hairpin loop of at least 3 nucleotides and N 4 , N 5 , and N 6 are in the loop region of the hairpin. 3. The oligonucleotide of claim 2 , wherein the hairpin structure comprises a double-stranded stem of at least four nucleotide base pairs, wherein the stem is fully double-stranded. 4. The oligonucleotide of claim 3 , wherein the stem comprises at least one G-clamp:G or guanadinium-G-clamp:G base pair. 5. The oligonucleotide of claim 4 , the stem is terminated by a G:C, G:U, G-clamp:G or guanadinium-G-clamp:G base pair. 6. The oligonucleotide of claim 1 , wherein the oligonucleotide comprises at least one modification selected from the group consisting of a sugar modification, a non-phosphodiester intersugar (or internucleoside) linkage, nucleobase modification, and ligand conjugation. 7. The oligonucleotide of claim 1 , wherein the oligonucleotide comprises a fluorescent reporter. 8. The oligonucleotide of claim 1 , wherein the 5′ end of the oligonucleotide is covalently linked to the 3′ end of the oligonucleotide. 9. The oligonucleotide of claim 1 , wherein N 1 and N 3 are independently selected purines and N 7 , N 8 , and N 9 are independently selected pyrimidines. 10. The oligonucleotide of claim 1 , wherein N 2 and N 4 are guanosine and N 5 is adenosine. 11. The oligonucleotide of claim 1 , wherein N 1 and N 5 are adenosine; N 3 is adenosine or uridine; N 2 and N 4 are guanosine; and N 6 , N 7 , N 8 , and N 9 are uridine. 12. The oligonucleotide of claim 1 , wherein the oligonucleotide comprises the (SEQ ID NO: 16) 5′-GGGCAGAGAUUUUGCCCGGAG-3′ or (SEQ ID NO: 17) 5′-GGGGUAGUGAUUUUACCCUGGAG-3′. 13. The oligonucleotide of claim 1 , wherein N 1 , N 3 , and N 6 are uridine; N 2 , N 5 , and N 7 are adenosine; N 4 is guanosine; and N 8 and N 9 are cytosine. 14. The oligonucleotide of claim 1 , wherein the oligonucleotide comprises the sequence (SEQ ID NO: 18) 5′-GGGGUCUAUGAUACCACCCCGGAG-3′. 15. A method for promoting miRNA processing of pri-miRNA to mature miRNA in a cell, wherein the miRNA is a let-7 family member, the method comprising contacting a cell with an isolated oligonucleotide of claim 1 .

Assignees

Inventors

Classifications

  • Double-stranded nucleic acids or oligonucleotides · CPC title

  • Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose · CPC title

  • C07H21/02Primary

    with ribosyl as saccharide radical · CPC title

  • Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT · CPC title

  • Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US9593141B2 cover?
The invention provides compositions and methods for regulating microRNA (miRNA) biogenesis. The invention also relates to compositions and methods for treating or preventing cancer in a subject in need thereof.
Who is the assignee on this patent?
President And Fellows Of Harvard Univ, Harvard College
What technology area does this patent fall under?
Primary CPC classification C07H21/02. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue Mar 14 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).